Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $66.22M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.07M
Average 1.40M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +1.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +23.9% | -5.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +1.5% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +6.5% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.9% over three years. Forward estimates point to EBIT at +6.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | $2.54 | Not rated | -7.1 | +68.18% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +128.36% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -9.45% |
Sutro Biopharma, Inc. NASDAQ:STRO | $162.83M | $9.82 | Not rated | -0.0 | +0.22% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | $3.71 | Not rated | 1.4 | +66.81% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +33.12% |
Coya Therapeutics, Inc. NASDAQ:COYA | $73.42M | $3.13 | Not rated | -3.9 | -50.97% |
Champions Oncology, Inc. NASDAQ:CSBR | $65.49M | $4.71 | Undervalued | -41.0 | -32.97% |
Clene Inc. NASDAQ:CLNN | $56.45M | $3.92 | Not rated | -2.1 | -57.24% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | $0.18 | Not rated | -1.5 | -35.83% |
Continue the stock analysis
Jump to another research area for this company.